Qualigen Therapeutics, Inc. (QLGN)
NASDAQ: QLGN · Real-Time Price · USD
3.870
+0.010 (0.26%)
At close: Nov 20, 2024, 4:00 PM
3.690
-0.180 (-4.65%)
After-hours: Nov 20, 2024, 7:44 PM EST
Qualigen Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
4
Market Cap
2.09M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Venus Concept | 67.20M |
| Xylo Technologies | 57.64M |
| Scorpius Holdings | 10.04M |
| Akanda | 2.51M |
| Fresh2 Group | 2.34M |
| Biodexa Pharmaceuticals | 104.90K |
QLGN News
- 20 days ago - Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024 - GlobeNewsWire
- 7 weeks ago - Qualigen Therapeutics, Inc. Announces management changes. - GlobeNewsWire
- 2 months ago - Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel - GlobeNewsWire
- 2 months ago - Univest Securities, LLC Announces Closing of $3.46 Million Registered Direct Offering for its Client Qualigen Therapeutics, Inc. (NASDAQ: QLGN) - GlobeNewsWire
- 2 months ago - Qualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public Offering - GlobeNewsWire
- 2 months ago - Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering - GlobeNewsWire
- 6 months ago - Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination - GlobeNewsWire
- 8 months ago - Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting - GlobeNewsWire